What's breaking now, across thousands of outlets.
Thousands of people visit emergency departments with headaches every year, but research suggests the way these visits are recorded may be hiding important clues about patients' needs.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
The French biotech Axoltis Pharma reported a Phase 2 failure in ALS on Tuesday morning, but suggested it found a small signal to move the drug forward amid a noisy dataset.
Kiffen ist inzwischen mit vielen Auflagen für Erwachsene erlaubt. Zugleich wächst der Markt für Cannabis als Medikament stark. Der neue Minister will dem einen Riegel vorschieben.
This summer’s COVID-19 wave may have reached its peak in some parts of the country, as major metrics report disease levels stagnating or starting to decline as of early September.
As the European Union reconsiders pesticide safeguards, South Africa has a crucial window to reform its nearly 80-year-old regulatory framework and protect public health and children's development.
The FDA’s long-awaited expedited investigational new drug pilot program began accepting applications Tuesday, with top agency officials incorporating public feedback into who should qualify.
A recently-launched Medicare experiment that pays for technology to help people manage chronic conditions is expanding.
